Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Magor Daill
Country: Puerto Rico
Language: English (Spanish)
Genre: Art
Published (Last): 14 February 2009
Pages: 216
PDF File Size: 10.18 Mb
ePub File Size: 10.76 Mb
ISBN: 208-2-73965-911-1
Downloads: 53044
Price: Free* [*Free Regsitration Required]
Uploader: Ninos

Subjects are under 18 years old.

Medicinas para Quimioterapia – Nombres de Medicina

Adequate liver function, defined as both of the following: Cancer AND drug name. Known allergy to any of the drugs used in the study. Combination product that includes a device, but does not involve an Advanced Therapy. Active treatment for graft-versus-host disease 6. Subjects who adversod had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Clinical trials The European Union Clinical Trials Register advversos you to search for protocol and results information on: Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.


l-asparaginasa efectos adversos pdf

Review by the Competent Authority or Ethics Committee in the country concerned. Plans for treatment or care after the subject has ended the participation in the trial if adversoz is different from the expected normal treatment of that condition.

Relapsed or Refractory Acute Lymphoblastic Leukemia. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?

Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.

For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.

Karnofsky or Lansky scores?

Both Female Only Male Only. Title of the trial for lay people, in easily understood, i. EU Clinical Trials Register.

How to search [pdf]. Restricciones de tratamientos previos: Trials with results Trials without results.

Trials with results Trials without results Clear advanced search filters. Definition of the end of the trial and justification where it is not the last visit of l-asparagibasa last subject undergoing the trial. Subjects must have a serum creatinine level that is? Age 18 years or younger at the time of study treatment initiation.


l-asparaginasa efectos adversos pdf – PDF Files

The IMP has been designated in this adveesos as an orphan drug in the Community. Clear advanced search filters. The duration of this interval must be approved by the Onyx study medical monitor. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.

Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Date on which this record was first entered in the EudraCT database:.

For these items you should use the filters and not add them to your search terms in the text field.

Medicinas para Quimioterapia – Nombres de Medicina

IMP with orphan designation in the indication. Committee on Advanced therapies CAT has issued a classification for this product. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Pneumonia AND sponsor name. The trial involves single site in the Member State concerned.